MedTrace Logo

Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE

NCT04505774 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 3591

Last updated 2024-12-30

Study results available
· View outcomes & findings →

Summary

This is a randomized, open label, adaptive platform trial to compare the effectiveness of antithrombotic and additional strategies for prevention of adverse outcomes in COVID-19 positive inpatients

Conditions

  • Covid19

Interventions

DRUG

theraputic heparin

increased dose of heparin above standard of care.

DRUG

prophylactic heparin

standard of care dose of heparin

DRUG

P2Y12

added P2Y12 inhibitor

DRUG

Crizanlizumab Injection

crizanlizumab injection

DRUG

SGLT2 inhibitor

sglt2 inhibitor

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Matthew Neal MD

    lead OTHER

Principal Investigators

  • Judith Hochman, MD · NYU Langone Health

  • Scott Solomon, MD · Brigham and Women's Hospital

  • Mikhail Kosiborod, MD · Saint Lukes

  • Jeffrey Berger, MD · NYU Langone Health

  • MATTHEW D NEAL, MD · University of Pittsburgh

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-04
Primary Completion
2023-08-31
Completion
2024-01-26
FDA Drug
Yes

Countries

  • United States
  • Brazil
  • Italy
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04505774 on ClinicalTrials.gov